Overview

• Precision medicine oncology firm's Q4 EPS and net income slightly beat analyst expectations

• Q4 collaboration revenue rose compared to the same period last year

• Company anticipates topline results from Phase 2/3 trial in metastatic uveal melanoma by March end

Outlook

• IDEAYA expects topline results from darovasertib trial by end of March 2026

• Company anticipates three Phase 3 trials for darovasertib by H1 2026

• IDEAYA plans IDE849 registrational study in SCLC by end of 2026

Result Drivers

• CLINICAL TRIAL PROGRESS - IDEAYA completed full enrollment in its Phase 2/3 trial for metastatic uveal melanoma, with topline results expected by March end

• PIPELINE EXPANSION - Co initiated IND filings for IDE034 and IDE574, expanding its clinical pipeline

• FINANCIAL POSITION - IDEAYA reported $1.05 bln in cash and equivalents, expected to fund operations into 2030

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $48.00, about 58.6% above its February 13 closing price of $30.27

Press Release: ID:nPn6yX2DKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)